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Despite having well-characterized disease-associated mutations, the mechanisms underlying the pro-
gressive bone marrow failure and cancer susceptibility of Fanconi anemia have been unclear. In this issue
of Cell Stem Cell, Ceccaldi et al. identify an overactive p53/p21 stress response and cell cycle arrest as an
underlying cause that starts during fetal development.Guido Fanconi originally described ‘‘per-
nicious anemia’’ in three siblings who
had large red blood cells, progressively
declining blood counts, and physical
anomalies (Fanconi, 1927). Fanconi ane-
mia (FA) is the paradigmatic constitutional
aplastic anemia and is characterized
functionally by decreased production of
all circulating blood cells and pathologi-
cally by a marrow devoid of hematopoi-
etic precursor cells. The stereotypical
clinical presentation is an infant or young
child with short stature, skin hyperpig-
mentation, hypoplastic thumbs, reduced
blood cell counts, and a fatty, unregener-
ative bone marrow. The diagnosis is
established by observing chromosomal
abnormalities in cells exposed to DNA
crosslinking agents (Shimamura and
Alter, 2010). FA patients die of the compli-
cations from low blood counts or from
leukemia and solid cancers. This pattern
of bone marrow failure (BMF) combined
with late myeloid malignancies occurs
in other inherited syndromes and in
acquired immune-mediated aplastic ane-
mia, making FA a useful model for
studying several conditions.
The FA genes (there were 15 at the
most recent count) were first identified
using the chromosomal phenotype ap-
parent in cell culture along with cell line
complementation, and more recently by
sequencing strategies. The FA gene prod-
ucts have been shown to constitute a
nuclear protein complex (but not yet an
enzymatic activity) and to define a path-
way of DNA repair that includes homolo-
gous recombination, nucleotide excision
repair, and mutagenic translation syn-
thesis (Moldovan and D’Andrea, 2009).
In this issue of Cell Stem Cell, Soulier
and colleagues reveal a link betweenunresolved DNA damage, an overactive
p53/p21 response, and the progressive
BMF that occurs in FA patients (Ceccaldi
et al., 2012). Although the p53 pathway
had been previously reported to promote
leukemogenesis in FA patients (Ceccaldi
et al., 2011), in this study the authors
reveal that overactive p53 also promotes
a decrease in the hematopoietic stem/
progenitor cell (HSPC) pool of FA patients
and support their claims using primitive
murine bone marrow cells.
Studies of FA are encumbered by the
difficulty in obtaining patient samples
of a rare disorder and because mouse
models do not accurately recapitulate
much of the human disease. Ceccaldi
et al. use a combination of in vitro
methods with FA CD34+ bone marrow
cells and in vivo assays using their mouse
bone marrow counterparts. First, they
observed a reduction in CD34+ HSPCs
in FA patients that worsened with age.
Given the role of the FA proteins in DNA
repair, they hypothesized that progres-
sive accumulation of DNA damage con-
tributed to their bone marrow failure.
Indeed, p53 activation was elevated in
primary blood cells from FA patients as
well as in bone marrow of Fanc-deficient
mice. To model the endogenous DNA
damage that accumulates in patients
over time, the authors next treated immor-
talized HSPCs from FA patients with
mitomycin C, a DNA crosslinking reagent
known to induce the damage response.
FA cells, but not control cells, arrested
in G2 phase due to unresolved DNA
damage during S phase. G2 arrest was
resolved in mitomycin C treated HPSCs,
and the cells instead underwent G0/G1
cell cycle arrest along with strong induc-
tion of p53 and p21. Silencing of p53 inCell StemFA cells resulted in increase DNA breaks
in cells arrested in G0/G1 after treatment
with mitomycin C.
They next tested whether inhibiting the
overactive p53 response rescued the
HSPC defect. Knockdown of p53 rescued
cell proliferation in both primary cells from
patients and the mouse model. Likewise,
depletion of p53 or p21 increased the
number of clonogenic progenitors in
CD34+ cells. Although marrow failure
does not occur until after birth, FA fetal
liver cells obtained from medical abor-
tions also had high levels of CDKN1A/
p21. Taken together, these data show
that an exaggerated physiologic stress
response results in the accumulation of
DNA damage, that this cellular stress
underlies progressive HSC depletion in
FA patients, and that genomic instability
may result if critical checks like p53 induc-
tion should fail.
That HSPC depletion starts during fetal
development and the fact that its circum-
vention later in life, as by p53 mutation or
deletion, creates genomic instability and
malignant hematopoietic cells is con-
sistent with the poor outcome of FA
in the clinic. Occasional FA patients do
show spontaneous improvement in blood
counts (Ceccaldi et al., 2011). Bone mar-
row functionmay be rescued by a somatic
reverse mutation or mitotic recombina-
tion, generating a chimeric HSPC com-
partment, and allowing repopulation of
the depleted marrow. A second mecha-
nism of rescue involves abrogation of
the G2 DNA damage checkpoint by lower
levels or inhibition of CHK1, permitting
cells to progress through the cell cycle
despite accumulated, unrepaired DNA
damage—but while blood counts may
improve, escape of the checkpoint wouldCell 11, July 6, 2012 ª2012 Elsevier Inc. 7
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transformation. In the current study, inhi-
bition of p53/p21 signaling rescued cells
from mitotic cycle arrest and, as in pre-
vious CHK1 experiments, allowed pro-
gression through cell cycle of cells
with increasing numbers of chromosomal
abnormalities.
These findings have several broader
implications for patients with several
different types of aplastic anemia. The
etiologies of constitutional and acquired
aplastic anemia are different, butmorpho-
logically they are indistinguishable, and
the pathophysiology in all types involves
a drastic reduction in HSC number and
a risk of malignant evolution with the
emergence of leukemic clones. In FA,
DNA repair pathways are implicated. In
Diamond-Blackfan anemia (DBA) and in
Schwachman-Bodian-Diamondsyndrome
(SBDS), ribosome assembly is defective
due to specific genetic lesions. In DBA,
as in FA, p53 activation occurs in re-
sponse to stress signals and appears crit-
ical in the reduction in HSPC number
(Narla and Ebert, 2010). In the telomero-
pathies, dyskeratosis congenita (DKC)
and a variety of subtle mutations in the
telomerase complex genes (TERT and
TERC), HSC loss occurs as senescence
or apoptosis is triggered by critical telo-
mere shortening (Calado and Young,
2009).
Progression to leukemia is frequent in
FA, DKC (the most severe of the telomere
diseases), SBDS, and, to a lesser extent,
DBA. AML that evolves in these constitu-
tional syndromes is almost invariably8 Cell Stem Cell 11, July 6, 2012 ª2012 Elsevassociated with aneuploidy and struc-
tural rearrangements, with a high preva-
lence of stereotypical cytogenetic abnor-
malities (Rochowski et al., 2012). Why
specific chromosomal patterns dominate,
whether chromosomal abnormalities in-
itiate the oncogenic process, and the rela-
tionship of chromosome aberrations to
genetic mutations, especially of p53 and
similarly protective genes, are not under-
stood. Moving forward, much will be
learned from sophisticated assays of
telomere length in cell populations and
single cells, as well as from genomic
sequencing of serial samples of HSCs
and their progeny in patients followed
over time. It is tempting to speculate that
the genetic alterations will reflect the
selective pressures under which defective
cells struggle, as, for example, in circum-
venting specific cell-cycle blocks (p53 in
FA and DKC) and telomere loss (telome-
rase upregulation in leukemia and many
cancer cells).
As highlighted in the current work in this
issue, the balance between the appro-
priate triggering of cell death due to stress
signals and its suppression by inactiva-
tion of p53, either through manipulation
in the laboratory or mutations in patients,
is delicate. Furthermore, these new data
reveal that in constitutional BMF, much
or most HSC loss may occur very early
in life, during fetal development or infancy.
Targeting these pathways molecularly is
appealing but not realistic. Gene therapy
in homozygous genetic disorders has
many technical obstacles, and even if
successful, would not target the entireier Inc.pool of premalignant cells. A less elegant
approach that has nonetheless been
proven in practice would be HSC trans-
plantation, which replaces defective cells.
Moreover, the utility of transplant is in-
creasing with the use of unrelated and
mismatched donors and improvements
in the management of complications.
The newly defined relationship between
mechanisms underlying BMF and the
development of cancer should provide
important insights into treating FA and
similar diseases.REFERENCES
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